Expected survival is decreased in hereditary hemorrhagic telangiectasia: Results from a population‐based registry study
Journal of Internal Medicine · 2026
DOI: 10.1111/joim.70134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, 2026. Verfasst von Cecilia Ahlström Emanuelsson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, Department of Ear, Nose and Throat Diseases, Skane University Hospital, Lund, Sweden. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Life Expectancy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fond för Morbus Oslerforskning vid Skånes universitetssjukhus..
Abstract (Originalsprache)
Background
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disorder associated with substantial morbidity.
Objectives
The aim of this study was to estimate mortality in a country without centralized national care for HHT patients. Moreover, we identified causes of death and estimated the prevalence of HHT in Sweden.
Methods
The Swedish National Patient Register (NPR) was used to identify individuals with HHT using the International Classification of Diseases (ICD) code I78.0. Cases included all individuals with this code between January 1, 2001 and December 31, 2003 ( n = 393). Five age‐ and gender‐matched controls from the general population were selected by Statistics Sweden (SCB) ( n = 1965). Cases and controls were followed for survival until 2018 using the Swedish National Cause of Death Register (DORS). To calculate prevalence, we identified all individuals with the ICD code I78.0 in the NPR over 12 years, from January 1, 2007 to December 30, 2018.
Results
Life expectancy for cases with HHT after age 30 was estimated at 73.0 (68.0–77.2) compared to 80.5 (79.1–82.0) years for controls. Ischemic heart diseases, diseases of arteries, arterioles, capillaries, and liver diseases were significantly more common causes of death among HHT patients. The prevalence of HHT was estimated at 9.3 per 100,000 over the 12 years.
Conclusion
HHT in Sweden is associated with markedly shorter expected survival compared to the general population, and known complications of HHT are among the most common causes of death. The estimated prevalence of HHT in Sweden was relatively low, possibly due to underdiagnosis of those with milder symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Science, Department of Ear, Nose and Throat Diseases, Skane University Hospital, Lund, Sweden.
- Department of Clinical Science, Intervention and Technology, Division of Ear, Nose and Throat Diseases, Karolinska Institutet, Stockholm, Sweden.
- Department of Translational Medicine, Lund University, Malmö, Sweden.
- Department of Medicine, Huddinge, Clinical Lung- and Allergy Research Unit, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Cecilia Ahlström Emanuelsson
Förderung
- Fond för Morbus Oslerforskning vid Skånes universitetssjukhus.
Zitieren
APA
Emanuelsson, C. A., Ehnhage, A., Holmström, M., Hagberg, O., & Westman, M. (2026). Expected survival is decreased in hereditary hemorrhagic telangiectasia: Results from a population‐based registry study. Journal of Internal Medicine. https://doi.org/10.1111/joim.70134
Vancouver
Emanuelsson CA, Ehnhage A, Holmström M, Hagberg O, Westman M. Expected survival is decreased in hereditary hemorrhagic telangiectasia: Results from a population‐based registry study. Journal of Internal Medicine. 2026. doi:10.1111/joim.70134
BibTeX
@article{Emanuelsson2026,
author = {Emanuelsson, Cecilia Ahlström and Ehnhage, Anders and Holmström, Mats and Hagberg, Oskar and Westman, Marit},
title = {Expected survival is decreased in hereditary hemorrhagic telangiectasia: Results from a population‐based registry study},
journal = {Journal of Internal Medicine},
year = {2026},
doi = {10.1111/joim.70134}
}
EUVIMED